.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Cerilliant
Julphar
Queensland Health
McKesson
Federal Trade Commission
Novartis
Teva
Citi
Fish and Richardson

Generated: February 19, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to United Kingdom Patent: 0126997.6

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes➤ Sign Up➤ Sign UpYYINDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA.
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes➤ Sign Up➤ Sign UpYYINDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes➤ Sign Up➤ Sign UpYYINDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes➤ Sign Up➤ Sign UpYYINDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-001May 10, 2013RXYesYes➤ Sign Up➤ Sign UpYYINDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-002Apr 30, 2015RXYesYes➤ Sign Up➤ Sign UpYYINDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-002Apr 30, 2015RXYesYes➤ Sign Up➤ Sign UpYYINDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER
Glaxo Grp LtdBREO ELLIPTAfluticasone furoate; vilanterol trifenatatePOWDER;INHALATION204275-002Apr 30, 2015RXYesYes➤ Sign Up➤ Sign UpYYINDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER
GlaxosmithklineTRELEGY ELLIPTAfluticasone furoate; umeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION209482-001Sep 18, 2017RXYesYes➤ Sign Up➤ Sign UpYYINDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA
GlaxosmithklineANORO ELLIPTAumeclidinium bromide; vilanterol trifenatatePOWDER;INHALATION203975-001Dec 18, 2013RXYesYes➤ Sign Up➤ Sign UpY
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist